Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
66.62B
Market cap66.62B
Price-Earnings ratio
15.48
Price-Earnings ratio15.48
Dividend yield
0.57%
Dividend yield0.57%
Average volume
1.23M
Average volume1.23M
High today
$640.82
High today$640.82
Low today
$632.05
Low today$632.05
Open price
$632.26
Open price$632.26
Volume
975.60K
Volume975.60K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$485.00
52 Week low$485.00

Stock Snapshot

Regeneron(REGN) stock is priced at $632.05, giving the company a market capitalization of 66.62B. It carries a P/E multiple of 15.48 and pays a dividend yield of 57.3%.

During the trading session on 2026-06-06, Regeneron(REGN) shares reached a daily high of $640.82 and a low of $632.05. At a current price of $632.05, the stock is 0.0% higher than the low and still -1.4% under the high.

Trading volume for Regeneron(REGN) stock has reached 975.6K, versus its average volume of 1.23M.

The stock's 52-week range extends from a low of $485.00 to a high of $821.11.

The stock's 52-week range extends from a low of $485.00 to a high of $821.11.

REGN News

Simply Wall St 1d
Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus

Kodiak Sciences (NasdaqGM:KOD) reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy. The company is accelerating regulato...

Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus
MarketWatch 2d
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

...

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TipRanks 2d
RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks...

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
25.8%
Sell
0%

More REGN News

Seeking Alpha 2d
Regeneron backed Parabilis seeks up to $476M in U.S. IPO

Parabilis Medicines (PBLS), a cancer drug developer backed by a recent research collaboration with Regeneron (REGN), has announced plans to raise up to $476M fr...

Regeneron backed Parabilis seeks up to $476M in U.S. IPO
TipRanks 3d
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Seeking Alpha 3d
CytomX gains as licensing deal with Regeneron expands

CytomX Therapeutics (CTMX) traded higher in the morning hours on Wednesday after the cancer drug developer announced an expanded collaboration and licensing agr...

CytomX gains as licensing deal with Regeneron expands
TipRanks 3d
CytomX Therapeutics expands licensing agreement with Regeneron

CytomX Therapeutics (CTMX) announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals (REGN) to create conditionally-act...

TipRanks 4d
Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

Simply Wall St 5d
Is Regeneron Quietly Redefining Its Pipeline Focus With These Niche Therapy Advances?

In late May 2026, Regeneron reported three pipeline updates: WHO prioritization of Inmazeb component maftivimab for Bundibugyo Ebola trials, EMA accelerated rev...

Is Regeneron Quietly Redefining Its Pipeline Focus With These Niche Therapy Advances?

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.